{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:49:32Z","timestamp":1790419772151,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30"],"award-info":[{"award-number":["P30"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Cancer-related neuropathic pain (CNP) affects an increasing proportion of cancer patients, given improved survival, but it remains difficult to treat. There are no studies on an extended intravenous ketamine protocol and its synergies with common neuropathy treatments to treat CNP. This study aims to 1) evaluate the safety and effectiveness of an intravenous ketamine protocol to treat refractory CNP and 2) uncover synergies between ketamine and common neuropathy treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a single-center, retrospective review of 57 patients and 192 infusions, with prospective follow-up on 14 enrolled patients during the coronavirus disease 2019 (COVID-19) pandemic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The etiologies of CNP were as follows: 13 from tumor compression, 25 with chemotherapy-induced peripheral neuropathy, 13 from surgery, and 6 from radiation therapy. Overall, 42 of 57 patients (73.7%) were responders, and 71.8% of responders received &amp;gt;3\u2009weeks of pain relief on their last infusion. Analysis of adjuvant treatments revealed that the combination of serotonin-norepinephrine reuptake inhibitors and ketamine resulted in an increase in responders compared with nonresponders (P\u2009&amp;lt;\u20090.01). Adverse events occurred in 32 of 192 infusions (16.7%). All side effects self-resolved or resolved with intervention per the adverse events protocol. During the pandemic, all 14 currently enrolled patients did not receive ketamine infusions. Thirteen of the 14 patients returned to baseline pain, with 61.5% increasing medications. All experienced worsened function, mobility, mood, or anorexia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Intravenous ketamine may be a safe and effective adjuvant treatment for CNP, especially with serotonin-norepinephrine reuptake inhibitors. Larger, prospective studies are warranted and should explore parameters to help prognosticate response to ketamine infusions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnab163","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T20:46:18Z","timestamp":1622753178000},"page":"1642-1650","source":"Crossref","is-referenced-by-count":8,"title":["Intravenous Ketamine for Cancer Pain Management, Including Flares During the COVID-19 Pandemic: A Retrospective Study"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5192-8533","authenticated-orcid":false,"given":"Daniel","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Rehabilitation and Regenerative Medicine, NewYork-Presbyterian Hospital\u2014University Hospital of Columbia and Cornell, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haffey","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Regenerative Medicine, NewYork-Presbyterian Hospital\u2014University Hospital of Columbia and Cornell, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Regenerative Medicine, NewYork-Presbyterian Hospital\u2014University Hospital of Columbia and Cornell, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"issue":"6","key":"2021072609400788300_pnab163-B1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3904\/kjim.2018.162","article-title":"Neuropathic cancer pain: Prevalence, pathophysiology, and management","volume":"33","author":"Yoon","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"4","key":"2021072609400788300_pnab163-B2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"J Pain"},{"issue":"2","key":"2021072609400788300_pnab163-B3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.ajp.0000210956.31997.89","article-title":"Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community","volume":"23","author":"Smith","year":"2007","journal-title":"Clin J Pain"},{"issue":"3","key":"2021072609400788300_pnab163-B4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"issue":"8","key":"2021072609400788300_pnab163-B5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/0269216312464408","article-title":"Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative\u2013Computerised Symptom Assessment Study","volume":"27","author":"Rayment","year":"2013","journal-title":"Palliat Med"},{"issue":"2","key":"2021072609400788300_pnab163-B6","first-page":"1","article-title":"Identification and treatment of neuropathic pain in patients with cancer","volume":"20","author":"Naleschinski","year":"2012","journal-title":"Int Assoc Study Pain"},{"issue":"1","key":"2021072609400788300_pnab163-B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bja\/aet208","article-title":"Neuropathic pain in cancer","volume":"111","author":"Fallon","year":"2013","journal-title":"Br J Anaesth"},{"issue":"6","key":"2021072609400788300_pnab163-B8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2021072609400788300_pnab163-B9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0304-3959(93)90161-H","article-title":"Contribution of central neuroplasticity to pathological pain: Review of clinical and experimental evidence","volume":"52","author":"Coderre","year":"1993","journal-title":"Pain"},{"issue":"5","key":"2021072609400788300_pnab163-B10","first-page":"521","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists","volume":"43","author":"Cohen","year":"2018","journal-title":"Reg Anesth Pain Med"},{"issue":"5","key":"2021072609400788300_pnab163-B11","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1097\/PR9.0000000000000674","article-title":"Ketamine for pain management","volume":"3","author":"Bell","year":"2018","journal-title":"Pain Rep"},{"issue":"2","key":"2021072609400788300_pnab163-B12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1213\/ANE.0000000000001787","article-title":"Intravenous ketamine infusions for neuropathic pain management: A promising therapy in need of optimization","volume":"124","author":"Maher","year":"2017","journal-title":"Anesth Analg"},{"issue":"4","key":"2021072609400788300_pnab163-B13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0885-3924(00)00194-9","article-title":"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study","volume":"20","author":"Mercadante","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2021072609400788300_pnab163-B14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/jpm.2011.0353","article-title":"Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: Considerations about the clinical research in palliative care","volume":"15","author":"Salas","year":"2012","journal-title":"J Palliat Med"},{"key":"2021072609400788300_pnab163-B15","first-page":"1465","article-title":"Ketamine as an adjuvant to opioids for cancer pain","volume":"6","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2021072609400788300_pnab163-B16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pain.2009.06.023","article-title":"Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1","volume":"145","author":"Sigtermans","year":"2009","journal-title":"Pain"},{"issue":"7","key":"2021072609400788300_pnab163-B17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"2021072609400788300_pnab163-B18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2253-5-2","article-title":"Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: A double-blinded, randomised, placebo controlled, crossover study of experimental pain","volume":"5","author":"Tucker","year":"2005","journal-title":"BMC Anesthesiol"},{"issue":"2","key":"2021072609400788300_pnab163-B19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.pbb.2012.09.011","article-title":"The role of the NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test","volume":"103","author":"Zomkowski","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"2021072609400788300_pnab163-B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.toxlet.2011.07.019","article-title":"Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation","volume":"206","author":"Chan","year":"2011","journal-title":"Toxicol Lett"},{"issue":"5","key":"2021072609400788300_pnab163-B21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.36076\/ppj.2014\/17\/425","article-title":"review of the role of genetic testing in pain medicine","volume":"17","author":"Trescot","year":"2014","journal-title":"Pain Physician"},{"key":"2021072609400788300_pnab163-B22","first-page":"1465","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"1","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"2021072609400788300_pnab163-B23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"2021072609400788300_pnab163-B24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0091-3057(02)00961-9","article-title":"Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain","volume":"74","author":"Baker","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"issue":"2\u20133","key":"2021072609400788300_pnab163-B25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tacc.2014.03.002","article-title":"Ketamine\u2014more mechanism of action than just NMDA blockade","volume":"4","author":"Sleigh","year":"2014","journal-title":"Trends Anaesth Critical Care"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnab163\/38656219\/pnab163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/7\/1642\/39312134\/pnab163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/7\/1642\/39312134\/pnab163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T09:41:11Z","timestamp":1627292471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/22\/7\/1642\/6292125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,6,4]]},"published-print":{"date-parts":[[2021,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnab163","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,6,4]]}}}